# US 2022/0088206 A1 · Controlled-release cnp agonists with increased nep stability

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0088206 A1
- Document ID: US20220088206A1
- Status: Published application
- Kind: A1
- Application number: 17/538,971
- Filed: 2021-11-30
- Published: 2022-03-24
- Earliest claimed: 2016-01-08
- Assignees: Ascendis Pharma Growth Disorders A/S
- Applicants: Ascendis Pharma Growth Disorders A/S
- Inventors: Kennett SPROGØE; Harald RAU; Ana BERNHARD; Ulrich HERSEL; Felix CLEEMANN; Thomas WEGGE
- Web page: https://patentgrep.com/patent/US20220088206A1

## CPC

- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method of treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more diseases which can be treated with a CNP agonist, comprising the step of administering to the patient a therapeutically effective amount of a controlled-release CNP agonist or a pharmaceutical composition comprising the controlled-release CNP agonist, wherein the controlled-release CNP agonist releases one or more CNP agonist and wherein the controlled-release CNP agonist has an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist.

### Claim 21 (depends on 20)

The method of claim 20, wherein the controlled-release CNP agonist has an at least 15-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist.

### Claim 22 (depends on 20)

The method of claim 20, wherein the controlled-release CNP agonist has an at least 25-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist.

### Claim 23 (depends on 20)

The method of claim 20, wherein the controlled-release CNP agonist releases at least one CNP agonist under physiological conditions with a release half-life of at least 6 hours.

### Claim 24 (depends on 20)

The method of claim 20, wherein the controlled-release CNP agonist releases at least one CNP agonist under physiological conditions with a release half-life of at least 24 hours.

### Claim 25 (depends on 20)

The method of claim 20, wherein the controlled-release CNP agonist releases at least one CNP agonist under physiological conditions with a release half-life of at least 48 hours.

### Claim 26 (depends on 20)

The method of claim 20, wherein the controlled-release CNP agonist releases at least one CNP agonist under physiological conditions with a release half-life of at least 168 hours.

### Claim 27 (depends on 20)

The method of claim 20, wherein the controlled-release CNP agonist comprises a CNP agonist selected from the group consisting of small molecules, natural products, oligonucleotides, polypeptides and proteins.

### Claim 28 (depends on 20)

The method of claim 20, wherein the CNP agonist is a polypeptide.

### Claim 29 (depends on 20)

The method of claim 20, wherein the CNP agonist is CNP.

### Claim 30 (depends on 20)

The method of claim 20, wherein the controlled-release CNP agonist is water-insoluble.

### Claim 31 (depends on 20)

The method of claim 20, wherein the controlled-release CNP agonist is selected from the group consisting of crystals, nanoparticles, microparticles, nanospheres and microspheres.

### Claim 32 (depends on 20)

The method of claim 20, wherein the controlled-release CNP agonist is a vesicle comprising at least one CNP agonist and wherein the vesicle is a micelle, liposome or polymersome.

### Claim 33 (depends on 20)

The method of claim 20, wherein the controlled-release CNP agonist is water-soluble.

### Claim 34 (depends on 20)

The method of claim 20, wherein the one or more diseases which can be treated with CNP is selected from the group consisting of achondroplasia, hypochondroplasia, short stature, dwarfism, osteochondrodysplasias, thanatophoric dysplasia, osteogenesis imperfecta, achondrogenesis, chondrodysplasia punctata, homozygous achondroplasia, camptomelic dysplasia, congenital lethal hypophosphatasia, perinatal lethal type of osteogenesis imperfecta, short-rib polydactyly syndromes, rhizomelic type of chondrodysplasia punctata, Jansen-type metaphyseal dysplasia, spondyloepiphyseal dysplasia congenita, atelosteogenesis, diastrophic dysplasia, congenital short femur, Langer-type mesomelic dysplasia, Nievergelt-type mesomelic dysplasia, Robinow syndrome, Reinhardt syndrome, acrodysostosis, peripheral dysostosis, Kniest dysplasia, fibrochondrogenesis, Roberts syndrome, acromesomelic dysplasia, micromelia, Morquio syndrome, Kniest syndrome, metatrophic dysplasia, spondyloepimetaphyseal dysplasia, neurofibromatosis, Legius syndrome, LEOPARD syndrome, Noonan syndrome, hereditary gingival fibromatosis, neurofibromatosis type 1, Legius syndrome, cardiofaciocutaneous syndrome, Costello syndrome, SHOX deficiency, idiopathic short stature, growth hormone deficiency, osteoarthritis, cleidocranial dysostosis, craniosynostosis, dactyly, brachydactyly, camptodactyly, polydactyly, syndactyly, dyssegmental dysplasia, enchondromatosis, fibrous dysplasia, hereditary multiple exostoses, hypophosphatemic rickets, Jaffe-Lichtenstein syndrome, Marfan syndrome, McCune-Albright syndrome, osteopetrosis and osteopoikilosis.

### Claim 35 (depends on 20)

The method of claim 20, wherein the one or more diseases which can be treated with CNP is selected from the group consisting of Muenke syndrome, Crouzon syndrome, Apert syndrome, Jackson-Weiss syndrome, Pfeiffer syndrome, and Crouzonodermoskeletal syndrome.

### Claim 36 (depends on 20)

The method of claim 20, wherein the disease is achondroplasia.
